UCL Shows Steriwave Effective Against Mucor Fungus

9th June 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

UCL Shows Steriwave Effective Against Mucor Fungus

UCL Researchers Present Steriwave Photodisinfection Efficacy Against Dangerous Mucor Fungus at 19th World Congress of the International Photodynamic Association in Shanghai, China

· Mucor fungal infections pose a serious risk to immunocompromised patients, such as those undergoing bone marrow transplants, with mortality rates often exceeding 50%.

Ondine Biomedical Inc. (AIM: OBI) announces new data from University College London (UCL), demonstrating the potent efficacy of Ondine's Steriwave® photodisinfection technology against the often-lethal fungus Mucor. The findings were presented in an abstract at the 19th World Congress of the International Photodynamic Association (IPA) in Shanghai, China.

Dr. Colin Hopper and Dr. Aashvi Joshi of University College London, Eastman Dental Institute, Oral and Maxillofacial Surgery, London, stated:

"Fungal infections, especially mucormycosis, are a serious threat in hospitals, with alarmingly high mortality rates and very few effective treatment options. The ability of Steriwave to rapidly and safely decolonize the nose of fungal pathogens represents a major advance in infection prevention, helping to protect patients from these life-threatening infections with affordable therapy."

Mucor fungal infections, particularly mucormycosis, pose a serious risk to immunocompromised patients, such as those undergoing bone marrow transplants, with mortality rates often exceeding 50%. Current therapies for mucormycosis are limited by high toxicity, incomplete efficacy, the need for aggressive surgery, frequent treatment failures, and persistently high mortality rates. These issues highlight the urgent need for new and more effective treatment strategies for the growing problem of drug-resistant fungal infections.

The research, conducted at UCL-where photodisinfection was invented by Emeritus Professor Michael Wilson in the late 1980s-showed that Ondine's Steriwave technology was able to completely inhibit the growth of all cells of Mucor in vitro, with very short treatment times. The results also demonstrated that Steriwave enhanced activity of other antifungals such as azoles, pointing the way to a combined topical and systemic approach to treatment of this invasive and deadly fungus.

By providing effective nasal decolonization of Mucor and other fungal pathogens, Steriwave photodisinfection offers a new approach to reduce patient risk and improve outcomes for those most vulnerable to invasive fungal disease. The ability to rapidly and safely eliminate these pathogens from the nasal passages is especially significant in hospital settings, where nasal pathogens are a major source of surgical site infections (SSIs) and healthcare-associated infections (HAIs), and where antimicrobial resistance is an escalating threat.

Ondine's patented Steriwave technology is already in use in hospitals across Canada and the UK for nasal decolonization to prevent SSIs and HAIs. The new findings from University College London provide further evidence of Steriwave's broad-spectrum efficacy and potential to significantly reduce the burden of healthcare-associated infections worldwide.

Enquiries:

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.